Evaluation of IL-17, TNF-alpha, RANKL Levels in Gingival Cervicular Fluid

February 1, 2022 updated by: Esin Özlek, Yuzuncu Yıl University

Evaluation of IL-17, TNF-alpha, RANKL Levels in Gingival Cervicular Fluid of Teeth With Periapical Lesions Diagnosed With Chronic Apical Periodontitis

Inflammatory process begins around root apex as a result of bacterial infection of pulp cavity in chronic apical periodontitis. Bone destruction can begin in apical region after immunological reactions at the end of inflammatory process, and radiolucent periapical lesion seems in this way. If bone destruction around apical region is in the rate of 30%, we can notice this difference eventually. Histological manifestations of periapical inflammation can be observed in the result of pulp necrosis and inflammation around apical region. Mocelular methods can determine the type of therapy in various diseases. Each region and tissue reserve specific host factors. Vast majority of pulpal inflammation was trigerred by microorganisms. Certain bacterial virulence factors may damage host tissue directly, other virulence factors can stimulate prolonged non-specific immune response causing tissue damage. In the last phase of infection, immunopathological destruction of pulp tissue is observed due to humoral response. IL-17 is an important inflammatory cytokine released from T cells of the immune system. TNF-alpha and RANKL are also mediators responsible for bone destruction metabolism. TNF is a cytokine mediating immunologic changes during periodontal disease. TNF induction stimulate secondary mediators taking part as chemotactic cytokines. TNF has two different types; TNF-alpha and TNF-beta. TNF-alpha is a polypeptide cytokine produced by macrophages and monocytes. TNF-alpha stimulates bone resorption . There has been limited researches analyzing GCF, blood and tissue of pulp, dentin-derived fluid and periapical fluid for molecular diagnosis so far. GCF is a fluid derived from gingival groove. This fluid contains a lot of host factors such as anticor, bacterial antigen, protein and cytokines. GCF sampling is a non-invasive method, it can be used to provide diagnostic information in all clinical cases. In this study, we will evaluate the levels of IL-17, TNF-alpha and RANKL in the gingival crevicular fluid of teeth with periapical lesion diagnosed with chronic apical periodontitis. Thus, it will be evaluated whether these markers can be used for diagnosis and follow-up of the disease in teeth with periapical lesions.

Study Overview

Status

Not yet recruiting

Detailed Description

It is planned to include volunteer patients who came to Van YYU Faculty of Dentistry, Oral and Maxillofacial Radiology Department between February and March 2022 for routine examination. Patients who applied to Yüzüncü Yıl University Faculty of Dentistry for treatment and met the study criteria will be included in the study by signing an informed consent form. 40 patients diagnosed with chronic apical periodontitis and having teeth with radiographic periapical lesions will be included in the study. Patients with periodontitis will not be included in the study.

GCF samples will be taken from the teeth diagnosed with chronic apical periodontitis and the contralateral teeth (from healthy teeth). The tooth which is resource of GCF will be isolated with cotton pellets. After the supragingival plaque is carefully removed with a curette, the tooth will be air-dried for 10 seconds, and periopaper strips will be placed in the gingival sulcus until resistance is felt. Periopaper strips will be removed from the gilgival sulcus after 1 minute. The levels of IL-17, TNF-alpha and RANKL from the samples in the gingival crevicular fluid will be evaluated.

Study Type

Observational

Enrollment (Anticipated)

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

It is planned to include volunteer patients who came to Van YYU Faculty of Dentistry, Oral and Maxillofacial Radiology Department for routine examination.

Description

Inclusion Criteria:

  • Healthy persons between the ages of 18 and 45 years
  • Mandibular molar teeth that were diagnosed with symptomatic irreversible pulpitis and periapical lesion

Exclusion Criteria:

  • Patients who are taken analgesic inflammatory drugs with in the last 12 hours
  • Pregnancy or lactation
  • Teeth with periodontal diseases
  • Teeth with sensitive to percussion and palpation
  • Teeth with root resorption
  • Teeth with immature/open apex

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
1
GCF samples will be taken from the teeth diagnosed with chronic apical periodontitis
GCF samples will be taken from the teeth diagnosed with chronic apical periodontitis
2
GCF samples will be taken from the collateral teeth (healthy teeth) of the teeth diagnosed with chronic apical periodontitis.
GCF samples will be taken from the teeth diagnosed with chronic apical periodontitis

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
IL-17 Level
Time Frame: 6 months
Concentration of IL-17 in GCF
6 months
TNF-alpha
Time Frame: 6 months
Concentration of TNF-alpha in GCF
6 months
RANKL
Time Frame: 6 months
Concentration of RANKL in GCF
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

February 1, 2022

Primary Completion (Anticipated)

March 30, 2022

Study Completion (Anticipated)

April 30, 2022

Study Registration Dates

First Submitted

January 17, 2022

First Submitted That Met QC Criteria

February 1, 2022

First Posted (Actual)

February 10, 2022

Study Record Updates

Last Update Posted (Actual)

February 10, 2022

Last Update Submitted That Met QC Criteria

February 1, 2022

Last Verified

February 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Apical Periodontitis

Clinical Trials on The teeth diagnosed with chronic apical periodontitis

Subscribe